Jan 09, 2020: Bayer and Exscientia Ltd. entered into a three-year multi-target collaboration, will work on early research projects combining Exscientia’s proprietary AI drug discovery platform and drug design know-how with Bayer’s data and drug discovery capabilities.
They aim is to identify and optimize novel lead structures for potential drug candidates to treat cardiovascular and oncological diseases. Exscientia may be entitled to receive up to EUR 240 million, together with upfront and research payments, near term and clinical milestones.
As part of the agreement, Exscientia might also receive sales royalties. Bayer owns the rights to novel lead structures generated as part of the collaboration.
AI has the potential to accelerate the drug discovery and improve the drug development productivity in terms of quality, cost and cycle time.
Exscientia’s AI-driven drug discovery technology provides novel chemical matter for difficult-to-address targets and could recognize novel drug candidates more powerfully through less optimization cycles.